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Abstract
Background: Chronic HBV infection is a major cause of Cirrhosis and an important risk factor to develop
hepatocellular carcinoma. The study is conducted to find out the changes in the lipid metabolism of HBV-cirrhosis
patients.
Methods: In the present study, serum lipid profiles of patients with HBV-cirrhosis were assessed by utilizing micro-
lab and gas chromatography, while risk factors for transmission of HBV-cirrhosis studied through the standard
questionnaire.
Results: The epidemiological and etiological risk factors strongly associated with HBV-cirrhosis patients compared to
controls, included as family history, shave from the barber, blood transfusion (without proper screening), mutual
sharing of household contents, positive surgery history, and dental treatment. The HBV-cirrhosis patients have
significantly lower level (p < 0.001) of lipid profile including total cholesterol (96.65 mg/dl), TAG (82.85 mg/dl), VLDL-C
(16.57 mg/dl), LDL-C (68.27 mg/dl), HDL-C (27 mg/dl) and total lipid (424.76 mg/dl) in comparison to controls,
indicating hypolipidemia in patients. The MELD score indicated mild prognostic values of the hepatic function for the
study group. The result of total fatty acid composition of HBV-cirrhotic patients with comparison of control subjects
reveals that palmitic (24.54 g/100 g) and palmitoleic acid (4.65 g/100 g) were significantly (p < 0.05) higher whereas
eicosatrienoic (0.09 g/100 g), arachidonic (3.57 g/100 g), linoleic (22.75 g/100 g) and α-linolenic acid (0.12 g/100 g)
were significantly lower. Marker for stearoyl-CoA desaturase (SCD = Δ9-desaturase) activity i.e. palmitoleic: palmitic (0.2)
and oleic: stearic acid (1.5) ratios, originated higher in HBV-cirrhotic patients, while PUFA: SFA (0.6) was lower in HBV-
cirrhosis patients as compared with control subjects. The serum SFA and MUFA were increased while PUFA were
reduced in both total and free form.
Conclusion: Present study concluded that hypolipidemia observed in HBV-cirrhosis patients, MELD were found to be
independent predictors of survival and alteration in fatty acid composition, possibly due to impairment in fatty acid
metabolism by enzymatic elongation and desaturation.
Keywords: Hepatitis B virus, Fatty acids, Cholesterol, GC-FID, Triacylglycerol, High density lipoprotein, Low density
lipoprotein, Very low density lipoprotein
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Background
Hepatitis B Virus (HBV) is an enveloped member of the
Hepadnaviridae family genus Orthohepadnavirus [1].
HBV infection with serious long-term morbidity and
mortality is one of the most important infectious dis-
eases in the world. More than 2 billion people have been
infected with HBV, and 360 million have chronically in-
fected with HBV Worldwide. Approximately 600,000
people died from acute or chronic HBV every year [2].
Chronic HBV infection is a major cause of Cirrhosis
along with important risk factor to develop Hepatocellu-
lar Carcinoma (HCC) [3].
Viral hepatitis cirrhosis is highly concerned and the
major cause of deaths (due to an infectious agent) in
Pakistan. Hepatitis B is the major causes of chronic liver
diseases, with the prevalence of 3–7%. The cirrhosis de-
veloped in 10–20% of chronic Hepatitis B patients
within 5–30 years [4].
The formation and clearance of lipoproteins occur in
the liver. From the diet and peripheral tissues it receives
cholesterol and fatty acids and converts them into lipopro-
tein complexes, eventually, releases into the blood circula-
tion. The liver diseases disrupt plasma lipids through
different ways. The plasma triglyceride and cholesterol re-
duced in chronic liver disease, due to the lower biosyn-
thetic capacity of lipoprotein [5]. Hepatic impairments are
caused by HBV, which in turn relates to the alterations of
lipid metabolism [6, 7]. Chronic hepatitis B, C, and cirrho-
sis of the liver, associated with impaired lipid metabolism
reduced total cholesterol and HDL-C in case-control stud-
ies. Changes in serum lipids were commonly found in pa-
tients with chronic liver disease [8].
The fatty acids play an important role in the pathogen-
esis of various diseases like metabolic disorders (Diabetes,
obesity, and cardiovascular disease) [9, 10]. Steatosis is de-
veloped in nonalcoholic fatty liver disease mainly due to
altered level of hepatic lipid, particularly a decrease in
polyunsaturated fatty acid (PUFA). The gene expression in
liver and skeletal muscles are influenced by PUFA, there-
fore, reduction occurs in fatty acid synthesis, triacylglyc-
erol storage, and fatty acid oxidation is increases. The
changes in tissues and PUFA contents moreover affect ei-
cosanoid synthesis, which might further promote the in-
flammation and steatosis [11].
Free fatty acids (FFAs) are significant mediators of
lipotoxicity; act as possible cellular toxins which lead to
the lipid over-accumulation. When lipids are over-
accumulated in non-adipose tissues, they may enter into
non-oxidative deleterious pathways which leads to cell
injury and death [12–14]. The elevated level of FFAs in
patients with NAFLD correlated with the severity of
disease [15].
Several studies have been conducted on dyslipidemia
of cirrhotic patients in developed countries, there is a
paucity of data in this regard in Pakistan. As there is a
high prevalence of cirrhosis in our country, this study
conducted to determine the epidemiological and etio-
logical risk factors severity, serum lipid profile, total and
free fatty acid composition among patients with HBV-
cirrhosis.
Methods
Diagnosed patients of HBV positive cirrhosis admitted to
Civil Hospital Hyderabad and Liaquat University of Medical
Health Sciences (LUMHS) Hospital Jamshoro were in-
cluded in this study. All patients were enrolled, have signed
a written consent. The risk factors for transmission of
HBV-cirrhosis disease were studied by a standard question-
naire, filled by all cases and controls. This study was ap-
proved by the ethnic committee, Institute of Biochemistry,
University of Sindh, Jamshoro. The flow chart of study is
presented in Fig. 1.
Diagnosis of HBV-cirrhosis patients
The physical examination of patients with HBV cirrhosis,
shows specific clinical signs & symptoms as ascites,
Fig. 1 Flow chart of the study
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abdominal wall vascular collaterals, hypertrophic osteoar-
thropathy, clubbing and asterixis. Constitutional symptoms
include weakness, fatigue, anorexia, and weight loss. The
ALT is the best screening test for identification of metabolic
disorder and drug-induced liver injury, but it has limitation
for predicting the degree of inflammation and estimating
the severity of fibrosis, the clinical evaluation of the patients
strongly favor to liver cirrhosis. The elevated level of
Alanine aminotransferase (ALT) was considered as indica-
tors of hepatocellular injury and responsible for the altered
lipid profile in HBV cirrhosis patients. Wong et al. [16] re-
ported that patients with abnormal ALT had a similar de-
gree of necroinflammation and fibrosis and their metabolic
profile was similar. ALT level largely reflected the degree of
hepatic steatosis instead of necroinflammation. No single
ALT cutoff could achieve reasonable sensitivity and specifi-
city in predicting the presence of NASH or significant liver
fibrosis. The present study includes all patients with posi-
tive HBV DNA, analyzed by PCR and having the higher
level of ALT. The ultrasonography and liver biopsy were
also performed by the hospitals and after interpretation of
sample slides microscopically the findings were evidence of
regenerative nodules of hepatocytes, surrounded by fibrous
connective tissue that bridges between portal tracts, con-
firm the presence of cirrhosis.
Age and gender matched controls with Hepatitis B
negative history (confirmed by non-reactive ELISA) were
included in the study.
Sample collection and analysis
5 ml intravenous blood samples were collected from
HBV-positive cirrhosis patients and healthy controls
(HCV negative) after 14 h overnight fasting. Serum was
separated and stored at −40 °C until analyzed for lipid
profile and fatty acids by micro-lab 300 and gas chroma-
tography (GC 8700, Perkin–Elmer Ltd). Lipid profile
performed by kit method (Merck, Germany) included
total cholesterol (TC), triacylglycerol (TAG), high density
lipoprotein–cholesterol (HDL-C), low density lipopro-
tein–cholesterol (LDL-C), very low density lipoprotein–
cholesterol (VLDL-C) and total lipid (TL) [17].
FA’s composition was analyzed as total fatty acid
(TFA) and free fatty acid (FFA) as per reported method
[18]. Peaks were identified by authentic standards sup-
plied by Fluka Chemika (Buchs, Switzerland). All sol-
vents and reagents used during the study were of
analytical grade. FA composition was reported as a rela-
tive percentage of the total peak area.
Exclusion criteria
After taking complete history, laboratory reports (includ-
ing thyroid profile, fasting blood sugar, serum urea, uric
acid, creatinine and complete picture of blood) and the
physical examination by the expert physician, patients
were excluded from study with malnutrition, hepatitis
co-infection, malabsorption, hypertension, diabetic and
hyperthyroidism, renal failure, malignancy and immuno-
globulin disorders.
Statistical analysis
The values were expressed as mean ± SD. For the associ-
ation between the groups (controls vs. patients) student’s
t-test or the Mann-Whitney U test was utilized with
SPSS version 15 (SPSS Inc. Chicago, IL). Multivariable
logistic regression analysis was performed by using the
SAS statistical software (version 9.1; SAS Institute, Inc.,
Cary, North Carolina) to determine the independent as-
sociation of each factor with HBV-cirrhosis patients.
Odds ratios and 95% confidence intervals (CI) were cal-
culated to estimate the risk factor. Tests for trend were
performed by using the means within each category in
the logistic-regression model. Quartile cut points were
determined by the distribution of the fatty-acid levels
among the referents, and the lowest quartile was used as
the reference category. The significant variation ob-
served when the P value was less than 0.05.
MELD score was calculated by the “Online UNOS
MELD calculator”:
MELD Score ¼ 0:957 Logeðcreatinine½mg=dlÞ þ 0:378
 Logeðtotal bilirubin½mg=dlÞ þ 1:120
 LogeðINRÞ þ 0:64:
Results
Among 55 patients, 25 patients were excluded due to
the consideration of exclusion criteria while remaining
thirty patients enrolled in the study. Sixty percent of
males included with overall male to female ratio of 1.5:
1. The median age 47.53 years (range, 29–70 years) was
also identified for the study group.
The epidemiological risk factors of the HBV-cirrhosis
patients and controls were strongly associated in multi-
variable analysis included as family history and shave
from a barber shop. The strong associations were also
observed among patients used to chew betel leaf, areca
nut and tobacco/Gutka in the dietary habits (Table 1).
The main etiologies of hepatitis B liver cirrhosis are
summarized in Table 2. Blood transfusion (without
proper screening), mutual sharing of household con-
tents, positive surgery history, and dental treatment were
positively associated with the disease.
It was prominent from the lipid profile data of cirrhosis
patients with hepatitis B that the confounding factors
(smoking, addiction of Betel leaf with areca nut and to-
bacco/gutka and moist powdered tobacco snuff) were cor-
related with disease. The strong correlation was seen in
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the smokers with HDL-C (R2 = 0.42) and the weak associ-
ation were seen with others confounding factors (Table 3).
For the patients with chronic liver disease specifically,
cirrhosis the Model for End-Stage Liver Disease (MELD)
were applied to estimate the disease severity and survival,
hence helpful for clinical professionals as decision-making
tools in patient care. Clinical history and demographic
data were collected during filling of the questionnaire, the
laboratory results like Serum Bilirubin, Serum Creatinine,
and INR were recorded. The patients were classed in three
categories as per their MELD scores. Although patients
had different levels for serum Bilirubin, Serum creatinine,
and INR but the laboratory results collected within the
groups as per their values. Five patients with serum biliru-
bin levels were found in between 2.7 mg/dl to 2.1 mg dl,
Serum Creatinine level more than 1.9 mg/dl have INR ra-
tion from 1.7 to 1.6; collectively their MELD score was
22.3 which predicted 19.6% mortality, further the 12 pa-
tients with MELD score 19.2 predicted 6% mortality and
remaining 13 patients with MELD score 16 had more than
5% of mortality prediction (Table 4).
The HBV-cirrhosis patients have a significantly lower
level (p < 0.001) of lipid profile including total cholesterol,












• No education 10 11 1.95 0.477–8.149 0.455
• Primary 4 6 1.43 0.234–8.762 0.960
• Matric 6 8 1.61 0.325–8.084 0.752
• Intermediate 3 10 0.64 0.100–3.853 0.869
• Graduation
and above
7 15 1.00 (Reference)
Marital status
• Married 18 30 1.00 0.360–2.790 1.000
• Unmarried 12 20 1.00 (Reference)
Family history
• Positive 20 10 8.00 2.567–25.834 0.0001
• Negative 10 40 1.00 (Reference)
Unani/homeopathic
treatment
• Yes 10 15 1.17 0.396–3.426 0.951
• No 20 35 1.00 (Reference)
Self-medication
• Yes 12 15 1.56 0.543–4.469 0.502
• No 18 35 1.00 (Reference)
Shaving
• Self 7 15 1.00 (Reference)
• Barber Shop 6 5 2.57 0.463–14.975 0.378
• Both self and
barber shop
5 8 1.34 0.255–7.078 0.975
Ear/Nose pricking
• Yes 12 20 1.00 0.358–2.782 1.000
• No 18 30 1.00 (Reference)
Addiction of
• Areca nut 10 6 2.19 0.608–8.154 0.287
• Betel leaf with
areca nut and
tobacco/Gutka




2 1 2.64 0.169–78.024 0.842
Smokers 10 11 1.77 0.575–5.488 0.394
Non smokers 20 39 1.00 (Reference)
















• Yes 11 7 3.56 1.061–12.220 0.038




• Yes 25 42 7.50 2.217–26.946 0.0001
• No 05 08 1.00 (Reference)
Surgery history
• Positive 9 5 3.86 1.009–15.374 0.048
• Negative 21 45 1.00 (Reference)
Dental treatment
• Yes 12 11 3.87 1.192–12.827 0.021
• No 18 39 1.00 (Reference)
Table 3 Regression analysis of confounding factors for lipid
profile in HBV cirrhosis patients
Confounding
factors
Coefficient of determination (R2)
Total
Cholesterol
TAG HDL-C LDL-C VLDL-C Total lipid
Smokers 0.15 0.11 0.42 0.11 0.18 0.26
Addiction of
Areca nut









0.01 0.05 0.05 0.01 0.05 0.10
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TAG, VLDL-C, LDL-C, HDL-C, and total lipid in com-
parison to controls (Table 5).
The result of TFA composition of HBV-cirrhotic pa-
tients with comparison of control subjects reveals that
palmitic and palmitoleic acids were significantly (p <
0.05) higher while eicosatrienoic, arachidonic, linoleic,
eicosapentaenoic, α-linolenic acids were significantly
lower in HBV-cirrhotic patients in comparison to
healthy subjects. The myristic, stearic, arachidic and
docosenoic acids were low and lignoceric, myristoleic,
docosapentaenoic and docosahexaenoic acids were ele-
vated but not significant. The nervonic and eicosapenta-
enoic acid was not detected in HBV-cirrhosis patients.
Marker for stearoyl-CoA desaturase (SCD = Δ9-desatur-
ase) activity i.e. palmitoleic: palmitic and oleic: stearic
acid ratios, was found higher in HBV-cirrhotic patients,
While PUFA: SFA was lower in HBV-cirrhosis patients
as compared with control subjects (Table 6).
The serum FFA profile of HBV-cirrhotic patient’s showed
significantly (p > 0.05) higher level of palmitic, palmitoleic,
stearic and myristoleic acid. The arachidic, docosenoic,
linoleic, arachidonic acids were significantly lower (p < 0.05)
in HBV-cirrhotic patients with comparison to controls. The
oleic, docosapentaenoic and docosahexaenoic acid were
higher and lignoceric, α-linolenic and eicosatrienoic lower
in patients but not significant (Table 7).
Odds ratios were calculated (Table 8) for HBV-
cirrhosis patients and controls by quartile of serum fatty
acids. Present study found an increased risk of HBV-
cirrhosis progression associated positively with increas-
ing levels of myristic, palmitic, stearic, palmitoleic, oleic
and docosenoic acids. The significant association be-
tween serum fatty acids and HBV-cirrhosis was found
when we compared the odds ratio for the highest quar-
tile with the lowest one, myristic acid 4.5 (95% CI: 0.2,
167.1; p for trend = 0.46), palmitic acid 2.5 (95% CI: 0.2,
48.4; p for trend = <0.01), stearic acid 6.0 (95% CI: 0.1,
1378; p for trend = 0.34), palmitoleic 5.0 (95% CI: 0.2,
297.8; p for trend = <0.01), oleic acid 4.0 (95% CI: 0.1,
361.0; p for trend = 0.19) and docosenoic acids odds ra-
tio was 4.3 (95% CI: 0.1, 423.2; p for trend = 0.23). On
the conflicting PUFA was inversely correlated with
HBV-cirrhosis progression odds ratio for the highest
quartile with the lowest one linoleic acid 0.6 (95% CI:
0.02, 19.3; p for trend = <0.01), α linolenic acid 0.2 (95%
CI: 0.01, 5.6; p for trend = 0.05), arachidonic acid 0.8
(95% CI: 0.03, 17.8; p for trend = <0.01) and eicosatrie-
noic acid odds ratio was 0.2 (95% CI: 0.005, 3.6; p for
trend = 0.02).
The total serum SFA and MUFA were increased sig-
nificantly (p < 0.05) in HBV cirrhotic patients compared
with normal controls and PUFA (n–3 and n–6) were
lower in HBV-cirrhotic patients in disparity to control
subjects (Fig. 2).







INR ratio MELD Score
5 2.7–2.1 >1.9 >1.7–1.6 22.3
12 2.0–1.8 1.8–1.6 1.5 19.2
13 <1.7 <1.5 <1.5 16
Table 5 Lipid profile of HBV cirrhosis patients in comparison of
controls
Lipid profile (mg/dl) Controls Patients
Total cholesterol 171.43 ± 17.7 96.65 ± 22.24*
VLDL-C 26.48 ± 5.0 16.57 ± 3.8*
LDL-C 110.7 ± 15.7 68.27 ± 17.8*
HDL-C 48.23 ± 7.1 27 ± 9.6*
Triglyceride 132.4 ± 25.4 82.85 ± 19.0*
Total Lipid 612.8 ± 47.9 424.76 ± 63.9*
* Values are mean ± standard deviation * Different from HBV-cirrhosis patients
with healthy controls, p < 0.001 (t test)
Table 6 Total fatty acids of HBV cirrhosis patients in comparison
of controls
Fatty Acids (g/100 g) Controls Patients
C-14:0 1.00 ± 0.9 0.88 ± 0.7
C-16 : 0 18.01 ± 4.0 24.54 ± 3.4*
C-18 : 0 16.00 ± 4.6 15.77 ± 3.4
C-20 : 0 0.78 ± 0.6 0.21 ± 0.3*
C-24 : 0 0.02 ± 0.06 0.07 ± 0.2
C-14 : 1 0.17 ± 0.4 0.26 ± 0.4
C-16 : 1 2.03 ± 1.6 4.65 ± 0.7*
C-18 : 1 22.18 ± 4.8 23.70 ± 2.9
C-22 : 1 1.75 ± 1.4 1.38 ± 0.9
C-24 : 1 0.18 ± 0.5 ND
C-18 : 2 28.72 ± 3.3 22.75 ± 3.2*
C-18 : 3 0.59 ± 0.9 0.12 ± 0.3
C-20 : 3 1.35 ± 0.9 0.09 ± 0.1*
C-20 : 4 6.31 ± 1.0 3.57 ± 0.8*
C-20 : 5 0.71 ± 0.3 ND*
C-22 : 5 0.33 ± 0.6 0.87 ± 0.8
C-22 : 6 0.50 ± 0.6 0.51 ± 0.7
C-16 : 1: C-16 : 0 0.1 0.2
C-18 : 1: C-18 : 0 1.3 1.5
PUFA : SFA 1.5 0.6
Values are mean ± standard deviation,* shows significant difference from HBV-
cirrhosis patients with comparison of healthy controls a p < 0.05 (t-test). myr-
istic acid (C14:0), myristoleic acid (C14:1), palmitic acid (C16:0), palmitoleic acid
(C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), α-linolenic
acid (C18:3), arachidic acid (C20:0), eicosatrienoic acid (C-20:3), arachidonic acid
(C20:4), eicosapentaenoic acid (EPA (C20:5), docosenoic acid (C22:1), docosa-
hexaenoic acid (DHA (C22:6), nervonic acid(C24:1), not detected (ND)
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The SFA, MUFA in free form were elevated and PUFA
was lower in HBV cirrhotic patients with the contrast of
healthy subjects. The Significant variation was seen in FFA
including SFA, MUFA, PUFA, and its n–6 form (Fig. 3).
Discussion
Most of the female patients were married and housewife.
The positive family history was significant (p = 0.0001)
risk factor associated with HBV-cirrhosis. Khan et al.
[19], reported that HBV can be transmitted from house
hold contents such as a tooth brush, razors, and nail
cutters. Mutual sharing of house hold contents with
positive family history arises as a major etiological factor
among patients.
Shave from barber shops showed strong association
with disease in present study. Janjua et al. [20] in a
cross-sectional study of barbers in Rawalpindi/Islamabad
in 1999, showed that only 13% of barbers knew that
hepatitis could be transmitted by contaminated razors.
The current study showed that blood transfusion is
strongly related to disease. Approximately 1.5 million
units of blood products were transfused every year in
Pakistan [21]. Data on the safety of this transfusion
process are scanty perhaps due to the lack of a system of
reporting infectious or non-infectious adverse events
[22]. Luby et al. [23] studied 24 randomly selected blood
banks in Karachi in 1995; while 95% had reagents and
equipment to test for HBV, only 55% could screen for
HIV and 23% for HCV. The positive association of tooth
extraction and the role of dental treatment was found as
self-determining viral hepatitis risk factor. The persons
with lower socioeconomic status exposed to viral hepa-
titis risk factors due to unhygienic inexpensive dental
Table 7 Free fatty acid profile of HBV cirrhosis patients in
comparison of controls
Fatty Acids (g/100 g) Controls Patients
C-14:0 1.29 ± 0.7 1.34 ± 0.9
C-16 : 0 19.84 ± 3.2 24.63 ± 5.1*
C-18 : 0 14.30 ± 5.6 17.80 ± 6.9
C-20 : 0 0.82 ± 0.5 0.16 ± 0.3*
C-24 : 0 0.11 ± 0.1 0.009 ± 0.03
C-14 : 1 0.14 ± 0.2 0.45 ± 0.4*
C-16 : 1 2.25 ± 0.8 3.58 ± 1.1*
C-18 : 1 22.50 ± 5.1 24.36 ± 3.1
C-22 : 1 1.70 ± 0.8 0.88 ± 0.6*
C-24 : 1 ND ND
C-18 : 2 27.99 ± 3.9 20.48 ± 3.8*
C-18 : 3 0.29 ± 0.1 0.07 ± 0.1
C-20 : 3 0.61 ± 0.4 0.18 ± 0.3
C-20 : 4 5.40 ± 2.4 2.55 ± 1.2*
C-20 : 5 0.54 ± 0.1 ND*
C-22 : 5 0.05 ± 0.1 0.12 ± 0.1
C-22 : 6 0.09 ± 0.2 0.33 ± 0.4*
Values are mean ± standard deviation,* shows significant difference from HBV-
cirrhosis patients with comparison of healthy controls a p < 0.05 (t-test). myr-
istic acid (C14:0), myristoleic acid (C14:1), palmitic acid (C16:0), palmitoleic acid
(C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), α-linolenic
acid (C18:3), arachidic acid (C20:0), eicosatrienoic acid (C-20:3), arachidonic acid
(C20:4), eicosapentaenoic acid (EPA (C20:5), docosenoic acid (C22:1), docosa-
hexaenoic acid (DHA (C22:6), nervonic acid(C24:1), not detected (ND)
Table 8 Odd ratios for HBV-cirrhosis patients and controls according to quartile of serum fatty acids
Fatty
acids
Odds ratio (95% confidence interval) P value
1st Quartile 2nd Quartile 3rd Quartile 4th Quartile 5th Quartile
Reference
C-14:0 1.00 1.5 (0.03–82.4) 2.2 (0.2–35.6) 3.0 (0.1–124.7) 4.5 (0.2–167.1) 0.46
C-16 : 0 1.00 2.5 (0.2–48.4) 1.7 (0.1–37.0) 1.7 (0.03–101.0) 2.5 (0.2–48.4) <0.01
C-18 : 0 1.00 3.0 (0.1–119.0) 4.0 (0.2–176.9) 3.0 (0.03–904.8) 6.0 (0.1–1378) 0.34
C-20 : 0 1.00 1.7 (0.1–26.2) 1.3 (0.02–84.0) 1.3 (0.1–31.2) 1.3 (0.02–84.0) 0.01
C-16 : 1 1.00 3.7 (0.2–101.2) 3.3 (0.2–59.4) 2.5 (0.04–196.7) 5.0 (0.2–297.8) <0.01
C-18 : 1 1.00 3.7 (0.2–143.1) 3.0 (0.1–141.2) 3.0 (0.03–904.8) 4.0 (0.1–361.0) 0.19
C-22 : 1 1.00 3.0 (0.1–119.0) 4.0 (1.2–176.9) 3.0 (0.03–904.8) 4.3 (0.1–423.2) 0.23
C-18 : 2 1.00 0.5 (0.02–8.8) 0.6 (0.03–13.5) 0.6 (0.01–50.0) 0.6 (0.02–19.3) <0.01
C-18 : 3 1.00 0.2 (0.005–3.7) 0.2 (0.01–5.6) 0.5 (0.01–25.4) 0.2 (0.01–5.6) 0.05
C-20 : 4 1.00 0.4 (0.01–10.4) 0.4 (0.01–10.4) 0.7 (0.02–19.3) 0.8 (0.03–17.8) <0.01
C-20 : 3 1.00 0.6 (0.03–9.4) 0.3 (0.01–6.6) 0.6 (0.01–29.6) 0.2 (0.005–3.6) 0.02
C-20 : 5 1.00 1.2 (0.02–62.1) 1.2 (0.02–62.1) 1.8 (0.1–25.9) 1.2 (0.07–19.9) 0.04
C-22 : 6 1.00 0.3 (0.01–4.9) 0.8 (0.1–12.9) 0.8 (0.02–41.6) 0.8 (0.02–41.6) 0.36
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cares such as tooth extraction which is occasionally ac-
complished by fake dentists [24].
We have also confirmed the strong association of
hepatitis B on hepatocellular carcinoma (HCC) risk by
regression analysis of confounding variables. The present
study showed the correlation of cigarette smoking with
lipid profile. Several theories have been proposed for the
role of cigarette smoking in liver carcinogenesis and its
potential interaction with viral infection [25, 26].
Cigarette smoke contains several chemicals that are me-
tabolized and activated as carcinogens in the liver and it
can, therefore, act as an initiator in the liver carcinogen-
esis, whereas HBV and HCV mainly act as a promoter
through chronic inflammation and cell proliferation
through chronic hepatitis and liver cirrhosis. In addition,
cigarette smoking may contribute to the progression
from chronic HBV and HCV infection to HCC [27].
Chuang et al. [28], reported that smoking seems to inter-
act with both HBV and HCV in determining HCC risk
by a pooled analysis of individual subject data, with ap-
propriate adjustment with other risk factors. Shafique et
al. [29], reported that raw areca nut users had signifi-
cantly, reduced HDL-C level. Sajid and Bano [30] re-
ported that deleterious effects of moist powdered
tobacco snuff usage caused altered lipid profile and de-
creased level of HDL-C in the serum of moist powdered
tobacco snuff users. Ahmed et al. [31], reported that
tobacco chewing has the more harmful effect on lipid
profile and lower levels of HDL was found in tobacco
chewers.
The MELD score for the patient’s refractory ascites
used for assessing the prognosis. However, even though
its interpretation can be subjective, ascites was shown to
be associated with the poorest prognosis [32]. It was felt
that patients with refractory ascites, normal creatinine,
and preserved hepatic function could be under-scored
with MELD. In particular, it was shown that persistent
ascites and low serum sodium identified a subset of pa-
tients with relatively low MELD score (below 21) and a
high risk of early death [33]. For reference, estimated 3-
month mortality, based on the MELD scores was prede-
fined [34]. MELD score 40 or more related to 71.3%
mortality, 30–39 for 52.6% mortality, 20–29 for 19.6%
mortality, 10–19 for 6.0% mortality and for <9 MELD
score 1.9% mortality .
The results of the present study indicated that serum
lipids level, total cholesterol, triglycerides HDL-C, LDL-
C, VLDL-C and total lipids significantly lower in HBV-
cirrhosis patients which indicate hypolipidemia in pa-
tients. The measured HDL-C is synthesized in the liver,
major injuries to hepatocytes, such as those caused by
alcohol consumption, chronic viral hepatitis or cirrhosis
of the liver, might produce abnormal liver function and
a moderate decrease in levels of total cholesterol and
HDL-C [35]. The significantly reduced level of serum
total cholesterol and triglycerides found in present study
HBV-cirrhosis patients has been confirmed earlier by
Ghadir et al. [36] conducted a study on cirrhosis patients
in Iran, showed that total cholesterol, HDL, LDL, and
triglycerides were all decreased. In patients with cirrho-
sis, the lower level of cholesterol indicated the severity
of liver cell injury, which is associated with impairment
of the synthetic ability of the liver. The patients have
shown that decreased levels of HDL-C increase the risk
of cardiovascular diseases (CVD) [37]. Viral liver infec-
tion can be considered a causing factor for atheroscler-
otic disease progression. The vascular changes seem to
start in the liver vasculature in relation to function
change rather than to the cause of liver impairment. A
reduced nitric oxide production was observed in the
hepatic vasculature of both animal and human cirrhotic
models. Positive associations among antibody titers, viral
hepatitis antigens and severity/mortality from cardiovas-
cular diseases have been supposed, although results are
still controversial. Serum concentrations of glucose, total
cholesterol and low-density lipoprotein (LDL) choles-
terol were significantly lower in anti-HCV-positive [38].
Metabolic changes caused by HBV-cirrhosis are associ-
ated with inflammation and fatty liver. In the current
study, we establish that the levels of eicosatrienoic, ara-
chidonic, linoleic, eicosapentaenoic, α-linolenic acids
Fig. 2 Comparison of serum total SFA, MUFA, PUFA including n–3
and n–6 fatty acids of controls and HBV-cirrhosis patients
Fig. 3 Comparison of free SFA, MUFA, PUFA including n–3 and n–6
fatty acids of controls and HBV-cirrhosis patients
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were significantly lower in HBV-cirrhotic patients. HBV
infection might induce essential FA deficiency in related
diseases, as indicated in the HepG2 cell line study [39].
The arachidonic acid was significantly decreased in
HBV-cirrhosis patients. Ristic-Medic et al. [40] reported
that in alcoholic liver cirrhosis plasma, arachidonic acid
deficiency was related to higher mortality rates in pa-
tients with advanced liver cirrhosis, and may be an im-
portant factor in the pathogenesis that altered renal,
immunological and coagulation functions in cirrhosis.
The reduction is observed in the total PUFA level and
PUFA/SFA ratio in HBV-cirrhosis patients. Possible rea-
sons include, a poor dietary intake of eicosapentaenoic
and linoleic acid and changes in Δ-5, Δ-6 and Δ-9 desa-
turase enzymes activity due to hepatocellular insuffi-
ciency [41] and an increased degradation of PUFA due
to lipid peroxidation [42].
The palmitic and palmitoleic acids were significantly
high and low stearic was found in HBV-cirrhosis pa-
tients. Alvaro et al. [43] found that an impaired FA
elongation in cirrhosis may be due to augmented activity
of Δ-9 desaturase and decreased the activity of elongase
resulted in the decrease level of stearic acid and in-
creased level of palmitoleic acid in cirrhosis patients [44,
45]. The low level of linoleic acid increases the activity
of Δ-9 desaturase [46], in addition, increased levels of
palmitoleic and oleic acid with the FA status usually
characterized by low linoleic acid [47] as observed in
malnutrition. High level of palmitic acid in present study
HBV-cirrhosis patients does not seem to be affected by
malnutrition.
The docosapentaenoic acid increased in current study
patients, similarly Puri et al. [48] reported a higher level
of docosapentaenoic acid in non-alcoholic fatty liver dis-
ease, due to impaired peroxisomal PUFA metabolism.
The palmitic, palmitoleic, stearic and myristoleic acids
are elevated in free form in HBV-cirrhosis patients. Most
of the literature has focused on the lipotoxic properties
of FFAs [49, 50]. Malhi et al. [51] indicated that FFAs
can have diverse cellular and metabolic effects particu-
larly stearic acid is more cytotoxic than palmitic acid.
Palmitoleic acid reverses the insulin resistance promoted
by palmitic acid. The higher level of stearic, palmitic,
palmitoleic and myristoleic acid in HBV-cirrhosis pa-
tients may represent an adaptive response to fatty acid
overload.
The immunomodulating activity is also found in fatty
acids [52, 53]. It is the n-3 fatty acids which contained
the most potent immunomodulatory activities, and
among the n-3 fatty acids, those from fish oil eicosa-
pentaenoic is more biologically potent than α- linolenic
acid [54]. The hepatitis B antigen reactivity may be
linked with impaired immunity and deficiency of immu-
nomodulating nutrients, it is possible that these agents
can alter immunity status causing a decrease in antigen
reactivity as observed in current study patients. It is pos-
sible that administration of n–3 fatty acid may reduce
infection rate and improve liver function recovery in
HBV-associated hepatic carcinoma patients after hepa-
tectomy. This improvement is associated with sup-
pressed production of pro-inflammatory cytokines in
these patients [55].
Conclusion
It is concluded that family history, shave from the barber
shop, blood transfusion, mutual sharing of household
contents, positive surgery history, and dental treatment
were the epidemiological and etiological risk factors,
strongly associated with HBV-cirrhosis. MELD were
found to be independent predictors of survival, with
mildly supportive impact for the clinician. Furthermore,
hypolipidemia, observed in HBV-cirrhosis patients with
an elevated level of SFA and low level of PUFA, possibly
due to alteration in fatty acid metabolism by enzymatic
elongation and desaturation.
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